📊 ANIX Key Takeaways
Is Anixa Biosciences Inc (ANIX) a Good Investment?
Anixa Biosciences is a pre-revenue pharmaceutical company burning cash at an unsustainable rate with minimal revenue generation ($210K), negative operating margins exceeding -1200%, and persistent operating losses. Despite strong balance sheet liquidity, the company is consuming capital rapidly with no clear path to profitability, making it a high-risk speculative entity dependent on successful drug development and future financing.
Anixa Biosciences shows very weak fundamentals, with minimal revenue, deeply negative operating and net margins, and continued cash burn that is far larger than its commercial base. While the balance sheet is currently lightly levered and liquid on paper, the low cash balance relative to negative free cash flow suggests limited runway and a high dependence on external funding unless operating losses narrow materially.
Why Buy Anixa Biosciences Inc Stock? ANIX Key Strengths
- Strong current ratio of 12.18x indicates adequate short-term liquidity to fund operations
- Low debt-to-equity ratio of 0.02x provides minimal financial leverage risk
- Substantial stockholders' equity of $15.1M provides some capital cushion for R&D investments
- Very low leverage with debt/equity of 0.02x
- Strong near-term liquidity ratios, with current and quick ratios both at 12.18x
- Slight year-over-year improvement in net income and diluted EPS
ANIX Stock Risks: Anixa Biosciences Inc Investment Risks
- Severe cash burn with negative operating cash flow of -$2.6M while generating only $210K in revenue
- Extreme negative profitability margins (-1293% operating margin, -1221% net margin) indicating substantial losses relative to minimal revenue
- High dependency on future financing and successful clinical trial outcomes with no demonstrated ability to generate sustainable revenue
- Cash runway limited to approximately 7 months at current burn rate if no additional capital is raised
- Revenue base is extremely small and showed no year-over-year growth
- Operating margin and free cash flow margin are deeply negative, indicating poor business economics
- Cash of $1.55M is low relative to negative operating cash flow of $2.61M, increasing financing risk
Key Metrics to Watch
- Quarterly operating cash flow trend and runway duration
- Revenue growth trajectory from pipeline programs and partnerships
- Clinical trial progress and regulatory milestones for lead drug candidates
- Changes in cash balance and capital raising activities
- Operating expense management and R&D spending efficiency
- Quarterly operating cash burn versus cash balance
- Revenue growth and operating loss trend
Anixa Biosciences Inc (ANIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.18x current ratio provides a solid financial cushion.
ANIX Profit Margin, ROE & Profitability Analysis
ANIX vs Healthcare Sector: How Anixa Biosciences Inc Compares
How Anixa Biosciences Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Anixa Biosciences Inc Stock Overvalued? ANIX Valuation Analysis 2026
Based on fundamental analysis, Anixa Biosciences Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Anixa Biosciences Inc Balance Sheet: ANIX Debt, Cash & Liquidity
ANIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Anixa Biosciences Inc's revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
ANIX Revenue Growth, EPS Growth & YoY Performance
ANIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $210.0K | -$2.5M | $-0.08 |
| Q2 2024 | $210.0K | -$2.3M | $-0.07 |
| Q3 2023 | $210.0K | -$2.5M | $-0.08 |
| Q2 2023 | $210.0K | -$2.3M | N/A |
| Q3 2022 | $513.0K | -$2.7M | N/A |
| Q2 2022 | $513.0K | -$2.4M | N/A |
| Q1 2022 | $513.0K | -$2.2M | N/A |
| Q3 2021 | $512.5K | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Anixa Biosciences Inc Dividends, Buybacks & Capital Allocation
ANIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Anixa Biosciences Inc (CIK: 0000715446)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANIX
What is the AI rating for ANIX?
Anixa Biosciences Inc (ANIX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANIX's key strengths?
Claude: Strong current ratio of 12.18x indicates adequate short-term liquidity to fund operations. Low debt-to-equity ratio of 0.02x provides minimal financial leverage risk. ChatGPT: Very low leverage with debt/equity of 0.02x. Strong near-term liquidity ratios, with current and quick ratios both at 12.18x.
What are the risks of investing in ANIX?
Claude: Severe cash burn with negative operating cash flow of -$2.6M while generating only $210K in revenue. Extreme negative profitability margins (-1293% operating margin, -1221% net margin) indicating substantial losses relative to minimal revenue. ChatGPT: Revenue base is extremely small and showed no year-over-year growth. Operating margin and free cash flow margin are deeply negative, indicating poor business economics.
What is ANIX's revenue and growth?
Anixa Biosciences Inc reported revenue of $210.0K.
Does ANIX pay dividends?
Anixa Biosciences Inc does not currently pay dividends.
Where can I find ANIX SEC filings?
Official SEC filings for Anixa Biosciences Inc (CIK: 0000715446) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANIX's EPS?
Anixa Biosciences Inc has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANIX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Anixa Biosciences Inc has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANIX stock overvalued or undervalued?
Valuation metrics for ANIX: ROE of -17.0% (sector avg: 15%), net margin of -1,221.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANIX stock in 2026?
Our dual AI analysis gives Anixa Biosciences Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANIX's free cash flow?
Anixa Biosciences Inc's operating cash flow is $-2.6M, with capital expenditures of $15.8K. FCF margin is -1,250.4%.
How does ANIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,221.4% (avg: 12%), ROE -17.0% (avg: 15%), current ratio 12.18 (avg: 2).